2015-2017
Ian Frew, PhD, University of Zurich, Switzerland
Using a novel mouse model of ccRCC to investigate Hif-1a and Hif-2a inhibition for cancer prevention and therapy
2015-2016
A.N.A. van der Horst-Schrivers, MD, PhD, University Medical Center Groningen in The Netherlands
Salivary, plasma meTanephRines and anxiEty levelS (STRESS)
2014-2016
Othon Iliopoulos, MD, Massachusetts General Hospital, Boston USA
Zebrafish Based Discovery of VHL Disease Targeting Drugs
2014-2015
Daniel Segal, PhD, Tel Aviv University, Tel Aviv, Israel
A novel chemical chaperone for treating the VHL cancer syndrome
2011-2012
Eleanor Rattenbury/Eamon Maher, M.D.,PhD U. of Birmingham, England
DNA changes that alter the function of the VHL protein and inhibit its ability to suppress cell growth.
Haifeng Yang, M.D., PhD, Cleveland, Clinic, USA
Drug Resistance in Clear Cell Renal Cancer-histone modifying enzyme JARID1C is mutated in ccRCC
2010-2011
Brenda Petrella, PhD. Dartmouth U., VA White Junction, Vermont, USA
MT1-MMP levels increase in the absence of the VHL protein enabling kidney cancer cells to metastasize.
2009-2010
Thera Links, MD. PhD, U. of Groningen, Netherlands
“Visualizing VEGF producing lesions in VHL”-radioactive labeled antibody based on bevacizuniab (avastin) binds to VEGF making it possible to see the concentration of VEGF on a PET scan.
Rachel Giles, PhD, U. of Utrecht, Netherlands
A Unique model for VHL-zebrafish without the VHL gene
2008-2009
Thera Links, MD, PhD, U. of Groningen, Netherlands
“Visualizing VEGF producing lesions in VHL”
Rupal Bhatt, M.D., PhD, Beth Israel Deaconess Hospital and Dana Farber/Harvard Cancer Center, Boston, USA
“Role of Interferon Gamma Pathway in resistance to Anti Angiogenesis Therapy”—blunting the resistance that develops to tyrosine kinase inhibitors (TCI) blockade of the VEGF pathway.
